143 related articles for article (PubMed ID: 38218173)
1. Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy.
De Giglio A; Di Federico A; Gariazzo E; Metro G
Med; 2024 Jan; 5(1):1-3. PubMed ID: 38218173
[TBL] [Abstract][Full Text] [Related]
2. Amivantamab plus Chemotherapy in NSCLC with
Zhou C; Tang KJ; Cho BC; Liu B; Paz-Ares L; Cheng S; Kitazono S; Thiagarajan M; Goldman JW; Sabari JK; Sanborn RE; Mansfield AS; Hung JY; Boyer M; Popat S; Mourão Dias J; Felip E; Majem M; Gumus M; Kim SW; Ono A; Xie J; Bhattacharya A; Agrawal T; Shreeve SM; Knoblauch RE; Park K; Girard N;
N Engl J Med; 2023 Nov; 389(22):2039-2051. PubMed ID: 37870976
[TBL] [Abstract][Full Text] [Related]
3. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
5. Amivantamab for the treatment of
Vyse S; Huang PH
Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
[TBL] [Abstract][Full Text] [Related]
6. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
[TBL] [Abstract][Full Text] [Related]
7. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
[TBL] [Abstract][Full Text] [Related]
8. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor JN; Patel JD; Wakelee HA; Levy BP; Borghaei H; Pellini B; Costello MR; Dowell JE; Finley G; Huang CH; Neal JW; Nieva JJ; Puri S; Socinski MA; Thomas C; Ross EA; Litwin S; Clapper ML; Treat J
Clin Lung Cancer; 2023 Nov; 24(7):e242-e246. PubMed ID: 37451930
[TBL] [Abstract][Full Text] [Related]
9. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
[TBL] [Abstract][Full Text] [Related]
10. Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.
Pacheco JM
Cancer Discov; 2021 Jul; 11(7):1617-1619. PubMed ID: 34284994
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
12. Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions.
Romero D
Nat Rev Clin Oncol; 2021 Oct; 18(10):604. PubMed ID: 34381206
[No Abstract] [Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
14. EGFR-Mutant NSCLC: Spotlight on Amivantamab.
Cancer Discov; 2023 Dec; 13(12):OF9. PubMed ID: 37878779
[TBL] [Abstract][Full Text] [Related]
15. Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC.
Passiglia F; Malapelle U; Normanno N; Pinto C
Cancer Treat Rev; 2022 Sep; 109():102438. PubMed ID: 35882108
[TBL] [Abstract][Full Text] [Related]
16. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang X; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950
[TBL] [Abstract][Full Text] [Related]
18. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
[TBL] [Abstract][Full Text] [Related]
19. The development of amivantamab for the treatment of non-small cell lung cancer.
Brazel D; Nagasaka M
Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
